| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.08 | 0.02 |
| mRNA | BIRB 0796 | GDSC1000 | pan-cancer | AAC | 0.078 | 0.02 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.093 | 0.02 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.03 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.03 |
| mRNA | HG-5-113-01 | GDSC1000 | pan-cancer | AAC | 0.099 | 0.03 |
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | -0.19 | 0.03 |
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | -0.079 | 0.03 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | 0.071 | 0.03 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.85 | 0.03 |